Latest Breaking News On - Tirtht patel - Page 2 : vimarsana.com

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Rezolute (NASDAQ:RZLT)

Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual

Tirtht patelChristen baglaneasAraj agrawalArshad khananiQuan dong nguyenStanford university school of medicineHead of ophthalmological clinical development at rezoluteRezolute incSecurities exchangeReno school of medicineByers eye instituteUniversity of nevadaStanford university schoolScientific advisoryClinical professorReno school

Tharimmune, Inc : Tharimmune Announces 1-for-15 Reverse Stock Split

BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in

Tirtht patelOmniab incExchange commissionCompany board of directorsTharimmune incNasdaq capital marketAnnual meetingPrivate securities litigation reform actRisk factorsAnnual reportIhr portfolio

Tharimmune Announces 1-for-15 Reverse Stock Split

Tharimmune Announces 1-for-15 Reverse Stock Split
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

Tirtht patelTharimmune incOmniab incExchange commissionCompany board of directorsNasdaq capital marketAnnual meetingPrivate securities litigation reform actRisk factorsAnnual report

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease.

Christen baglaneasQuan dong nguyenAraj agrawalArshad khananiTirtht patelReno school of medicineSecurities exchangeUniversity of nevadaRezolute incStanford university school of medicineHead of ophthalmological clinical development at rezoluteByers eye instituteStanford university schoolScientific advisoryClinical professorReno school

Rezolute Inc (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402

Rezolute Inc (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Araj agrawalQuan dong nguyenArshad khananiChristen baglaneasTirtht patelStanford university school of medicineByers eye instituteUniversity of nevadaSecurities exchangeRezolute incReno school of medicineHead of ophthalmological clinical development at rezoluteStanford university schoolScientific advisoryClinical professorReno school